1357476-67-5
C9H9BrF3N
268.07
1.473±0.06
Breast cancer
Alpelisib
4/29/2033 (Alpelisib)
PI3Kα
Availability: | |
---|---|
DESCRIPTION
As the first-in-class oral PI3K inhibitor, Alpelisib offers targeted therapy for advanced or metastatic hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation. This groundbreaking drug provides a personalized approach, enhancing treatment outcomes while minimizing toxicity. By incorporating Alpelisib into your pharmaceutical portfolio, you can champion precision medicine and make a significant impact on patients' lives. Embrace Alpelisib and join the fight against breast cancer with innovation and compassion.
content is empty!